Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapansutrile for acute gout flare
2024-518844-20-00Phase 3Authorised
- Sponsor
- Olatec Therapeutics LLC
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial in gout comparing Dapansutrile with Placebo (2 arms). Primary endpoint: Change from baseline in target joint pain intensity at 72 hours. Planned start Oct 2023; status: authorised.
02
Drugs
dapansutrile
03
Conditions
gout
Beyond the preview
Go deeper on 2024-518844-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518844-20-00.